期刊文献+

IL-17、胱抑素C、同型半胱氨酸在帕金森病患者中的表达及意义 被引量:7

Expression of serum IL-17, cystatin C, homocysteine in patients of Parkinson's disease and their clinical significance
下载PDF
导出
摘要 目的探讨白细胞介素17(IL-17)、胱抑素C(CysC)、同型半胱氨酸(Hcy)在帕金森病患者中的表达及意义。方法选择2010年1月至2013年12月期间68例帕金森病(PD)患者为观察组。选择健康人群42例为对照组。将68例PD患者按病情进展分为早期20例(H-Y分期<2);中期22例(2≤H-Y分期<3)和晚期26例(H-Y分期≥3)。将68例PD患者分为认知功能障碍组32例(A组)和无认知功能障碍组36例(B组)。统计两组受试者血清IL-17、CysC、Hcy含量,对血清IL-17、CysC、Hcy与年龄、患病年限、H&Y评分、BMI进行相关性分析。结果 A组、B组血清CysC、IL-17、Hcy水平明显高于对照组(P<0.01),且A组血清CysC、IL-17、Hcy水平高于B组(P<0.01);晚期组血清CysC、IL-17、Hcy水平最高(P<0.01),中期组血清CysC、IL-17、Hcy水平均高于早期组(P<0.01);观察组患者血清IL-17、CysC、Hcy水平与患病年限呈正相关(P<0.05),与H-Y分期呈正相关(P<0.05);血清IL-17、CysC、Hcy水平之间均呈正相关(P<0.05)。结论 IL-17、CysC、Hcy与PD的发病及进展密切相关,可反应病情的严重程度,在PD的进展中起一定作用。 Objective To study the expression of serum cystatin C, interleukin-17(IL-17), homocysteine(Hcy) in patients of Parkinson's disease(PD) and their clinical significance. Methods From January 2010 to December 2013, 68 patients of PD were selected as the observation group. Forty-two healthy people were selected as the control group. The 68 PD patients were divided into three stages according to the progress of the disease: early stage group(20 cases, H-Y stage2), medium stage group(22 cases, 2≤H-Y3), advanced stage group(26 cases, H-Y≥3).The 68 PD patients were divided into the cognitive dysfunction group(32 cases, group A) and without cognitive dysfunction group(36 cases, group B). Serum CysC, IL-17, Hcy contents were detected. The correlation between serum CysC, IL-17, Hcy and age, disease duration, HY score, BMI were analyzed. Results Serum Cys B, IL-17, Hcy levels in group A and group B were significantly higher than those in the control group(P〈0.01), and these levels were significantly higher in group A than group B(P〈0.01). Serum CysC, IL-17, Hcy levels in the advanced stage group was the highest(P〈0.01), followed by medium stage group and then early stage group(P〈0.01). Serum IL-17, CysC, Hcy levels were positively correlated with disease duration(P〈0.05) and H-Y score(P〈0.05). There were positive correlations between serum IL-17, CysC, Hcy levels(P〈0.05). Conclusion IL-17, CysC, Hcy are closely related to the pathogenesis and progress of PD, which can reflect the severity of the disease and play a role in the development of PD.
出处 《海南医学》 CAS 2015年第13期1894-1897,共4页 Hainan Medical Journal
关键词 帕金森病 胱抑素C 白细胞介素17 同型半胱氨酸 Parkinson's disease Cystatin C Interleukin-17(IL-17) Homocysteine(Hcy)
  • 相关文献

参考文献15

  • 1Ceravolo R, Cossu G, Bandettini di Poggio M,et al. Neuropathyand levodopa in Parkinson's disease: evidence from a multicenterstudy [J]. Mov Disord, 2013,28(10): 1391-1397.
  • 2甘蓉,张玉虎,聂坤,王丽娟.帕金森病患者认知障碍与血浆同型半胱氨酸水平的相关性研究[J].中华老年心脑血管病杂志,2012,14(3):231-232. 被引量:28
  • 3Kumudini N, Uma A, Naushad SM, et al. Association of seven func-tional polymorphisms of one-carbon metabolic pathway with totalplasma homocysteine levels and susceptibility to Parkinson's dis-ease among South Indians [J]. Neurosci Lett, 2014, 568: 1-5.
  • 4Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helico-bacter pylori in Parkinson's disease [J]. J Neurol, 2013,260(12):2974-2980.
  • 5Dorszewska J,Prendecki M, Lianeri M, et al. Molecular effects of1-dopa therapy in Parkinson's disease [J]. Curr Genomics, 2014,15(1): 11-17.
  • 6Ataie A, Ataee R, Mansoury Z, et al. Homocysteine intracerebroven-tricular injection induces apoptosis in the substantia nigra cells andParkinson's disease likebehavior in rats [J]. Int J Mol Cell Med,2013,2(2): 80-85.
  • 7徐金敏,陈静,毛成洁,杨亚萍,刘春风.血清胱抑素C的水平变化与帕金森病的关系[J].中华医学杂志,2014,94(11):804-807. 被引量:10
  • 8Rozycka A, Jagodzinski PP, Kozubski W, et al. Homocysteine leveland mechanisms of injury in Parkinson's disease as related to MTH-FR, MTR, and MTHFD1 genes polymorphisms and L-dopa treat-ment [J]. Curr Genomics, 2013,14(8): 534-542.
  • 9晁宁,孙亮,于会艳,赵丽姣,曾湘豫,顾卫红,杨泽,秦斌.5,10亚甲基四氢叶酸还原酶基因C677T多态性与帕金森病伴发高同型半胱氨酸血症的关系[J].中华老年医学杂志,2014,33(2):121-125. 被引量:3
  • 10Santiago JA, Scherzer CR, Potashkin JA. Network analysis identi-fies SOD2 mRNA as a potential biomarker for Parkinson's disease[J]. PLoS One. 2014,9(10): el09042.

二级参考文献23

  • 1傅毅,陈生弟,刘建荣,倪培华,应雅韵.帕金森病患者血浆同型半胱氨酸水平及其代谢相关酶基因多态性分析[J].中国神经科学杂志,2004,20(6):450-455. 被引量:13
  • 2Wald DS,Kasturiratne A,Simmonds M,et al. Serum homocysteine and dementia:Meta analysis of eight cohort studies inclu- ding 8669 participants. Alzheimer' s Dement, 2011,7 : 412-417.
  • 3Winblad B, Palmer K, Petersen RC, et al. Mild cognitive im pairment beyond controversies, towards a consensus : Report of the International Working Group on Mild Cognitive Impair ment. Journal of Internal Medicine, 2004,256 : 240-246.
  • 4Sobe C, Abe T, Terayama Y, et al. L Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson' s disease. J Clin Neurosci, 2010,17 : 71 7- 721.
  • 5Rodriguez-Oroz MC, Lage PM, Sanchez Mut J, et al. Hbmoeys- teine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging and genetic study. Movement Disorders,2009,24 : 1437-1444.
  • 6Zoccolella S, Lamberti SV, Iliceto G, et al. H yperhomocysteine mia in L-Dopa treated patients with Parkinson' s disease: Potential implications in cognitive dysfunction and dementia? Current Medicinal Chemistry, 2010,17 : 3253-3261.
  • 7Allain P, Le Bouil A, Cordillet E, et al. Sulfate and cysteine levels in the plasma of patients with Parkinsons disease[J]. Neurotoxieology, 1995, 16: 527-529.
  • 8Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases[J]. J Neurol Neurosurg Psychiatry, 1992,55 : 181-184.
  • 9Kang SS, Wong PW, Malinow MR. Hyperhomocyst (e) inemia as a risk factor for occlusive vascular disease[J]. Annu Rev Nutr, 1992, 12:279-298.
  • 10Ueland PM, Refsum H, Stabler SP, et al. Total homocysteine in plasma of serum: methods and clinical applications[J]. Clin Chem, 1993, 39:1764- 1779.

共引文献38

同被引文献59

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部